Core Insights - Laboratory Corp reported third-quarter 2025 adjusted earnings per share of $4.18, an increase from $3.50 a year ago, surpassing the consensus of $4.18 [1] - Sales rose 8.6% year-over-year to $3.56 billion, also beating the consensus of $3.56 billion [1] - The sales increase was attributed to organic revenue growth of 6.2%, acquisitions net of divestitures at 1.7%, and foreign currency translation contributing 0.7% [1] Financial Performance - Adjusted operating income for the quarter was $396.6 million, representing 11.1% of revenue [1] - The company revised its fiscal year 2025 adjusted earnings guidance from $16.05-$16.50 to $16.15-$16.50, compared to the consensus of $16.32 [3] - LabCorp lowered its 2025 sales guidance from $14.08 billion-$14.23 billion to $13.97 billion-$14.05 billion, against the consensus of $14.01 billion [3] Growth Projections - LabCorp forecasts 2025 sales growth of 7.4%-8%, down from prior guidance of 7.5%-8.6% [3] - The guidance includes Diagnostics Laboratories sales growth of 7.2%-7.8% and Biopharma Laboratory Services sales growth of 5.7%-7.1% [4] Market Position - Analyst Andrew F. Brackmann from William Blair reiterated an Outperform rating, noting LabCorp's steady organic growth in diagnostics and a solid M&A pipeline [4] - The company is positioned for long-term earnings growth, supported by a steady dividend and resilient valuation multiple [4] Stock Performance - Laboratory Corp's stock is down 5.23% at $261.25 as of the last check on Tuesday [5]

Core Insights - Quest Diagnostics has raised its full-year profit and revenue forecast due to strong demand for its diagnostic tests [1] Company Summary - The company is experiencing robust demand for its diagnostic tests, which has led to an optimistic revision of its financial outlook for the year [1]

Core Insights - Labcorp Holdings Inc. will release its financial results for Q3 2025 on October 28, 2025, before market opening [1] - A conference call and webcast will be held at 9 a.m. ET on the same day to discuss the results [1][2] - The earnings press release and financial information will be available on the Labcorp Investor Relations website [1] Company Overview - Labcorp is a global leader in laboratory services, providing innovative and comprehensive solutions to healthcare providers, pharmaceutical companies, and researchers [4] - The company employs nearly 70,000 individuals and operates in approximately 100 countries, supporting over 75% of new drugs approved by the FDA in 2024 [4] - Labcorp performs more than 700 million tests annually for patients worldwide [4]

Private medical labs in France could face cuts in government reimbursement, slashing their operating profit. https://t.co/yGQ9mcBEeg ...

Core Insights - Labcorp has launched Test Finder, a generative AI tool developed in collaboration with Amazon Web Services (AWS), aimed at simplifying lab test selection for healthcare providers [1][3] - The tool allows providers to ask questions in plain language and receive curated test recommendations, enhancing user experience and allowing more time for patient care [1][2] Industry Context - Laboratory testing is crucial in healthcare, influencing nearly 70% of clinical decisions, yet providers spend over three hours daily on administrative tasks, which could be redirected to patient interaction [2] - A survey by the American Medical Association indicates that 57% of physicians see automation as a significant opportunity for AI in healthcare [2] Product Features - Test Finder utilizes Amazon Bedrock and large language model technology, providing a detailed list of suggested tests based on user input [3] - The tool aims to ease the burden on clinicians by offering a faster, more intuitive way to navigate complex test menus and identify appropriate tests [3] - Labcorp's implementation of AI is positioned as a transformative step in healthcare, enhancing clinical workflow optimization and enabling quicker decision-making that can improve patient care outcomes [3] Company Overview - Labcorp is a global leader in laboratory services, supporting healthcare providers, pharmaceutical companies, and researchers with diagnostic insights [4] - The company employs nearly 70,000 individuals and operates in approximately 100 countries, conducting over 700 million tests annually [4]

Core Insights - Labcorp has received CE-marking for PGDx elio™ tissue complete, making it the first and only test of its kind in the EU for comprehensive solid tumor profiling, significantly enhancing access to personalized cancer care for approximately 2.7 million cancer patients annually in the EU [1][2] Group 1: Product and Regulatory Approval - The PGDx elio™ tissue complete test has been cleared by the U.S. FDA and is now CE-marked under the EU's new In Vitro Diagnostic Regulation (IVDR), supporting guideline-based care for patients with solid tumors [2][3] - The test can analyze multiple biomarkers simultaneously, even from limited tissue samples, which can expedite patient management plans and potentially improve prognoses [2][3] Group 2: Impact on Healthcare and Biopharma - This achievement reflects Labcorp's commitment to advancing precision medicine and improving patient care, setting a new standard for quality and performance in cancer diagnostics [3] - The CE-marking allows for broader laboratory access across the EU, facilitating personalized cancer care and providing biopharma partners with a reliable solution for clinical trials [3][4] Group 3: Company Overview - Labcorp is a global leader in laboratory services, supporting healthcare providers and pharmaceutical companies with diagnostics and drug development, performing over 700 million tests annually [6]

Financial Performance - Q2 2025 - Total Adjusted EBITDA for Q2 2025 was $627.8 million[6], compared to $574.6 million in Q2 2024[6], an increase - The company's Q2 2025 revenue, as reported, reached $3.5273 billion[21], a 9.5% increase year-over-year from $3.2209 billion in Q2 2024[21] - Adjusted earnings per share for Q2 2025 was $4.35[23], compared to $3.94 in Q2 2024[23] Revenue Breakdown and Growth - Enterprise revenue, as reported, for Q2 2025 was $3.527 billion[8], reflecting a 9.5% year-over-year growth[8] - Diagnostics Laboratories revenue, as reported, for Q2 2025 was $2.749 billion[8], showing an 8.9% year-over-year growth[8] - Biopharma Laboratory Services revenue, as reported, for Q2 2025 was $785 million[8], a significant 11% increase year-over-year[8] Outlook for 2025 - The company projects full-year 2025 revenue for Labcorp Enterprise to be between $13.98 billion and $14.13 billion[18], representing a 7.5% to 8.6% increase versus 2024 results[18] - The company anticipates adjusted EPS for 2025 to be in the range of $16.05 to $16.50[18], a 10.1% to 13.2% increase compared to 2024[18] Biopharma Laboratory Services Metrics - The Trailing Twelve Month (TTM) Net Orders ending June 30, 2025, for Biopharma Laboratory Services reached $3.34 billion[17], with a Net Book-to-Bill ratio of 1.11x[17] - As of June 30, 2025, the backlog for Biopharma Laboratory Services was $8.71 billion[17], with an estimated $2.71 billion expected to convert to revenue in the next twelve months[17]

Core Viewpoint - Labcorp Holdings (LH) has been upgraded to a Zacks Rank 2 (Buy), indicating a positive outlook based on rising earnings estimates, which significantly influence stock prices [1][3]. Earnings Estimates and Stock Price Impact - The Zacks rating system emphasizes the importance of earnings estimate revisions, which are strongly correlated with near-term stock price movements [4][6]. - Institutional investors utilize earnings estimates to determine the fair value of stocks, leading to buying or selling actions that affect stock prices [4]. Labcorp's Earnings Outlook - For the fiscal year ending December 2025, Labcorp is expected to earn $16.05 per share, with a 0.3% increase in the Zacks Consensus Estimate over the past three months [8]. - The upgrade reflects an improvement in Labcorp's underlying business, which is likely to drive the stock price higher as investors respond positively to this trend [5][10]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with a strong historical performance, particularly for Zacks Rank 1 stocks, which have averaged a +25% annual return since 1988 [7]. - Labcorp's upgrade to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, suggesting a strong potential for market-beating returns in the near term [9][10].

Core Viewpoint - Quest Diagnostics (DGX) has been upgraded to a Zacks Rank 2 (Buy), indicating a positive outlook on its earnings estimates, which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Price Movement - The Zacks rating system reflects changes in earnings estimates, which are strongly correlated with near-term stock price movements, particularly due to institutional investors' reliance on these estimates for valuation [4][6]. - An increase in earnings estimates typically leads to higher fair value calculations for stocks, prompting institutional investors to buy or sell, thus affecting stock prices [4]. Company Performance and Outlook - The upgrade for Quest Diagnostics signifies an improvement in its underlying business, which is expected to drive the stock price higher as investors respond positively to this trend [5][10]. - Analysts project that Quest Diagnostics will earn $9.70 per share for the fiscal year ending December 2025, with a slight increase of 0.1% in the Zacks Consensus Estimate over the past three months [8]. Zacks Rank System - The Zacks Rank system categorizes stocks based on earnings estimate revisions, with only the top 20% of stocks receiving a "Strong Buy" or "Buy" rating, indicating superior potential for market-beating returns [9][10]. - The Zacks Rank 2 for Quest Diagnostics places it among the top 20% of stocks covered by Zacks, suggesting a favorable outlook for the stock in the near term [10].

Financial Results Announcement - Labcorp Holdings Inc. will release its financial results for the second quarter of 2025 before the market opens on July 24, 2025 [1] - A conference call and webcast will be held at 9 a.m. ET on the same day to discuss the results [1] Webcast Details - The call will be available via live webcast on the Labcorp Investor Relations website, with registration required for dial-in access [2] - Participants are encouraged to join 10 minutes early, but can register and join at any time during the call [2] Replay Information - A replay of the webcast will be accessible approximately two hours after the live event and will remain available until July 11, 2026 [3] Company Overview - Labcorp is a global leader in laboratory services, aiding healthcare professionals and researchers in decision-making [4] - The company employs nearly 70,000 individuals and operates in approximately 100 countries, supporting over 75% of new drugs approved by the FDA in 2024 [4] - Labcorp conducts more than 700 million tests annually for patients worldwide [4]